Table 2 Therapeutic data and disease activity states at cross-sectional visit in patients still receiving etanercept (n = 422)a
| Â | No assessed | No (%) positive |
|---|---|---|
Concomitant therapies | ||
 Systemic corticosteroids | 422 | 20 (4.7) |
 Intra-articular corticosteroids | 422 | 11 (2.6) |
 Methotrexate | 422 | 200 (47.4) |
 Salazopyrin | 422 | 3 (0.7) |
 Azathioprine | 422 | 1 (0.2) |
Disease activity states – Formal definitions | ||
 Wallace criteria for inactive disease | 392 | 164 (41.8) |
 Wallace criteria for inactive disease without  acute phase reactants | 420 | 214 (51) |
 Magni-Manzoni criteria for low disease activity | 420 | 267 (63.6) |
Disease activity states – JADAS10 | ||
 Inactive disease | 422 | 196 (46.4) |
 Low disease activityb | 422 | 270 (64) |
 Moderate disease activity | 422 | 103 (24.4) |
 High disease activity | 422 | 49 (11.6) |
Disease activity states – cJADAS10 | ||
 Inactive disease | 422 | 205 (48.6) |
 Low disease activityb | 422 | 246 (58.3) |
 Moderate disease activity | 422 | 117 (27.7) |
 High disease activity | 422 | 59 (14) |
Patients with no active joints | 422 | 289 (68.5) |
Patients with no swollen joints | 422 | 313 (74.2) |
Patients with no tender joints | 422 | 299 (70.9) |
Patients with no restricted joints | 422 | 253 (60) |
Patients with physician’s VAS = 0 | 422 | 239 (56.6) |
Patients with ESR < 20 mm/h | 398 | 321 (80.7) |
Patients with normal CRP | 402 | 341 (84.8) |
Patients with JADI Articular = 0 | 419 | 324 (77.3) |
Patients with JADI Extraarticular = 0 | 419 | 364 (86.9) |